Mohammad Kawsar Sharif Siam

Dr. Mohammad Kawsar Sharif Siam

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Translational Oncology
Verified
Journal Article
Open access
ZAZarema Albakova
Zarema Albakova
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
PSPradeep Kumar Sacitharan
Pradeep Kumar Sacitharan
RZRustam H. Ziganshin
Rustam H. Ziganshin
DRDmitriy Y. Ryazantsev
Dmitriy Y. Ryazantsev
ASAlexander M. Sapozhnikov
Alexander M. Sapozhnikov
• High expression of extracellular heat shock proteins (HSPs) indicates highly aggressive tumors. • HSP profiling of extracellular vesicles (EVs) derived from various biological fluids and released by immune cells may open new perspectives for an identification of diagnostic, prognostic and predictive biomarkers of cancer. • Identification of specific microRNAs targeting HSPs in EVs may be a promising strategy for the discovery of novel biomarkers of cancer.

24 August 2019 in Biomolecules
Verified
Journal Article
Open access
PDF file
DKDr. Eva Rahman Kabir
Dr. Eva Rahman Kabir
SMShannon Moreino
Shannon Moreino
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
The coming wave of patent expiries of first generation commercialized biotherapeutical drugs has seen the global market open its doors to close copies of these products. These near perfect substitutes, which are termed as “biosimilars”, do not need to undergo intense clinical trials for their approval. However, they are mandated to produce identical similarity from their reference biologics in terms of clinical safety and efficacy. As such, these biosimilar products promise to foster unprecedented access to a wide range of life-saving biologics. However, seeing this promise be fulfilled requires the development of biosimilars to be augmented with product trust, predictable regulatory frameworks, and sustainable policies. It is vital for healthcare and marketing professionals to understand the critical challenges surrounding biosimilar use and implement informed clinical and commercial decisions. A proper framework of pharmacovigilance, education, and scientific exchange for biologics and biosimilars would ensure a dramatic rise in healthcare access and market sustainability. This paper seeks to collate and review all relevant published intelligence of the health and business potential of biosimilars. In doing so, it provides a visualization of the essential steps that are required to be taken for global biosimilar acceptance.

4 August 2020 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
ASAnusree Sarker
Anusree Sarker
MSMohammad Manzur Sharif Sayeem
Mohammad Manzur Sharif Sayeem
The overexpression of Akt1 (RAC-alpha serine/threonine-protein Kinase) and Akt2 (RAC-beta serine/threonine-protein Kinase) is a hallmark of Oral Squamous Cell Carcinoma (OSCC). Because of the elevated frequency of OSCC occurrence in South Asian countries, novel therapeutic approaches are indispensable. Drugs that inhibit the overexpression of Akt1 and Akt2 proteins in Akt pathway and do not cause reduced expression of MAOB can be leads for OSCC treatment. In this study, Akt1, Akt2 and MAOB were targeted and 100 CYP inhibitors were screened through several in silico approaches and Galuteolin and Linarin were identified as potential leads for OSCC treatment as they inhibited Akt1 proteins with strong binding affinities of −12.3 and −11.5 kcal/mol respectively and also Akt2 proteins with strong binding affinities of −11.4 and −11.1 kcal/mol respectively, but they did not inhibit MAOB. Decreased expression of MAOB in tissues causes OSCC but overexpression is also responsible for other types of diseases and cancers. From the investigation of CYP inhibitors against MAOB, five CYP inhibitors- Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin have expressed inhibitory action against MAOB without any interference with Akt1 and Akt2. This study mainly represents that Galuteolin and Linarin in the Akt pathway can be perceived for OSCC treatment and other five CYP inhibitors – Diosmetin, Acacetin, Epicatechin, Eriodictyol and Capillin for the treatment of other diseases and cancers caused by overexpression of MAOB. ADMET properties of CYP inhibitors obtained from admetSAR 2.0 and were compared with reference drugs for validation. Communicated by Ramaswamy H. Sarma.

7 January 2013 in Journal of Pharmaceutical Health Services Research
Verified
Journal Article
Closed access
PDF file
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
AKAbbas Khan
Abbas Khan
Tahir Mehmood KhanTahir Mehmood Khan
Tahir Mehmood Khan

15 April 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
DCDipankor Chatterjee
Dipankor Chatterjee
MRMostafijur Rahman
Mostafijur Rahman
ASAnik Kumar Saha
Anik Kumar Saha
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
MSMohammad Umer Sharif Shohan
Mohammad Umer Sharif Shohan

1 February 2021 in Heliyon
Verified
Journal Article
Open access
DKDr. Eva Rahman Kabir
Dr. Eva Rahman Kabir
NMNashrah Mustafa
Nashrah Mustafa
NNNahid Nausheen
Nahid Nausheen
MSMohammad Kawsar Sharif Siam
Mohammad Kawsar Sharif Siam
ESEasin Uddin Syed
Easin Uddin Syed
The COVID-19 situation had escalated into an unprecedented global crisis in just a few weeks. On the 30th of January 2020, World Health Organization officially declared the COVID-19 epidemic as a public health emergency of international concern. The confirmed cases were reported to exceed 105,856,046 globally, with the death toll of above 2,311,048, according to the dashboard from Johns Hopkins University on the 7th of February, 2021, though the actual figures may be much higher. Conserved regions of the South Asian strains were used to construct a phylogenetic tree to find evolutionary relationships among the novel virus. Off target similarities were searched with other microorganisms that have been previously reported using Basic Local Alignment Search Tool (BLAST). The conserved regions did not match with any previously reported microorganisms or viruses, which confirmed the novelty of SARS-CoV-2. Currently there is no approved drug for the prevention and treatment of COVID-19, but researchers globally are attempting to come up with one or more soon. Therapeutic strategies need to be addressed urgently to combat COVID-19. Successful drug repurposing is a tool that uses old and safe drugs, is time effective and requires lower development costs, and was thus considered for the study. Molecular docking was used for repurposing drugs from our own comprehensive database of approximately 300 highly characterized, existing drugs with known safety profile, to identify compounds that will inhibit the chosen molecular targets - SARS-CoV-2, ACE2, and TMPRSS2. The study has identified and proposed twenty seven candidates for further in vitro and in vivo studies for the treatment of SARS-CoV-2 infection.